As a major member of dual PI3K/mTOR inhibitors, NVP-BEZ235 has undergone Phase I/II trials for the treatment of some malignancies including renal carcinoma (Mayer and Arteaga, 2016). The gene discussed is MTOR; the disease is renal carcinoma.